Ceribell (CBLL) lifts 2026 outlook after 33% Q2 revenue growth to $28.1M

Rhea-AI Filing Summary

Ceribell, Inc. reported strong top-line growth for the quarter ended June 30, 2026. Total revenue was $28.1 million, up 33% from $21.2 million a year earlier, driven by new account additions and higher utilization across its installed base. Product revenue reached $21.2 million and subscription revenue $6.9 million, both rising about 30% year over year. The company ended the quarter with 712 active accounts.

Profitability remains negative but margins are high. Gross profit was $25.9 million with a 92% gross margin, aided by manufacturing efficiencies, a new Vietnam line, and one-time tariff refunds. Operating expenses increased 37% to $45.9 million as Ceribell invested in commercial expansion, R&D, and legal costs. Net loss widened to $19.3 million, or $0.51 per share, while Adjusted EBITDA loss was $9.8 million.

The balance sheet showed $129.3 million in cash, cash equivalents, and marketable securities at June 30, 2026. Ceribell subsequently entered a new credit facility providing access to up to $60 million in committed capital. The company raised its 2026 revenue outlook to $114–$117 million, implying about 28–31% growth. It also highlighted multiple FDA 510(k) clearances and a CMS New Technology Add-On Payment for its delirium monitoring solution, effective October 1, 2026.

Positive

• Revenue grew 33% year over year in Q2 2026 to $28.1 million, with both product and subscription revenue increasing around 30%, indicating strong demand and account utilization.
• Ceribell achieved a 92% gross margin, up from 88%, supported by cost reductions, a Vietnam manufacturing line, and tariff refunds, demonstrating highly profitable unit economics despite losses.
• The company raised full-year 2026 revenue guidance to $114–$117 million, implying about 28–31% growth over the prior year, reflecting confidence in business momentum.
• Cash, cash equivalents, and marketable securities totaled $129.3 million, and a new credit facility adds up to $60 million of committed capital, enhancing financial flexibility.
• Multiple FDA 510(k) clearances for detection algorithms and next-generation hardware, plus a CMS New Technology Add-On Payment for delirium monitoring, support product adoption and reimbursement.

Negative

• Net loss increased to $19.3 million in Q2 2026 from $13.6 million a year earlier, and Adjusted EBITDA loss remained substantial at $9.8 million, showing ongoing lack of profitability.
• Operating expenses rose 37% year over year to $45.9 million, driven by commercial expansion, higher headcount, and legal costs, outpacing revenue growth and pressuring earnings.
• Accumulated deficit reached $259.4 million as of June 30, 2026, and total assets declined to $166.3 million from $195.8 million at year-end 2025, reflecting continued cash burn.

Filing Explained

The credit-facility disclosure clarifies that the $60 million is debt capacity—$30 million term loan plus $30 million revolving facility—while a separate $25 million is available only at the lender’s discretion; no draw or stock issuance is reported.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 total revenue: $28.1 million Q2 2026 gross margin: 92% Q2 2026 net loss: $19.3 million +5 more

8 metrics

Q2 2026 total revenue $28.1 million Three months ended June 30, 2026; up 33% from $21.2 million in Q2 2025

Q2 2026 gross margin 92% Gross profit of $25.9 million on $28.1 million revenue; improved from 88% in 2025

Q2 2026 net loss $19.3 million Net loss for the three months ended June 30, 2026; $0.51 per share

Q2 2026 Adjusted EBITDA loss $9.8 million Adjusted EBITDA (non-GAAP) for the three months ended June 30, 2026

Cash and marketable securities $129.3 million Cash, cash equivalents, and marketable securities as of June 30, 2026

2026 revenue guidance $114–$117 million Raised full-year 2026 revenue outlook; about 28–31% growth over prior year revenue

New credit facility capacity $60 million committed Comprises $30 million term loan and $30 million revolver, plus $25 million uncommitted

Active accounts 712 Total active accounts at the end of the second quarter of 2026

Key Terms

Adjusted EBITDA, New Technology Add-On Payment, 510(k) clearances, International Emergency Economic Powers Act, +1 more

5 terms

Adjusted EBITDA financial

"Adjusted EBITDA loss (a non-GAAP measure) for the second quarter of 2026 was $9.8 million"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

New Technology Add-On Payment regulatory

"Received New Technology Add-On Payment (NTAP) for delirium monitoring solution from Centers for Medicare & Medicaid Services"

A new technology add-on payment is a temporary extra reimbursement that Medicare gives hospitals for genuinely new, high-cost medical devices, drugs or procedures that aren’t yet fully covered by standard hospital payments. It matters to investors because this top-up helps hospitals afford and adopt costly innovations—similar to a short-term subsidy—boosting revenue prospects for device makers and speeding market uptake, which can affect sales, valuation, and adoption timelines.

510(k) clearances regulatory

"Received U.S. Food and Drug Administration 510(k) clearances for Epileptiform Abnormality Detection algorithm"

A 510(k) clearance is a U.S. Food and Drug Administration (FDA) decision that allows a medical device to be marketed because it is shown to be similar enough to an already approved device. For investors, a 510(k) is a regulatory green light that can shorten time to sales and reduce development costs—like getting permission to sell a new model that works much like an established product—but it is not the same as a full safety or effectiveness guarantee.

International Emergency Economic Powers Act regulatory

"one-time benefit of tariff refunds previously paid under the International Emergency Economic Powers Act"

A U.S. law that gives the president broad authority to control trade, financial transactions, and assets during a declared national emergency, such as by imposing sanctions, freezing property, or restricting exports and imports. For investors it matters because those powers can suddenly block deals, cut off access to markets or funds, and change the value of companies or securities much like an emergency brake that can stop or reroute economic activity overnight.

electroencephalography medical

"a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs"

Electroencephalography is a medical test that uses small sensors on the scalp to record the brain’s electrical activity over time, like an EKG for the brain. Investors care because EEG data can be used in drug and device development, patient diagnosis, and monitoring treatment effects; strong EEG results can influence clinical success, regulatory approvals, and market adoption, affecting a company’s value and risk profile.

Earnings Snapshot

Total revenue: $28.1 million · Guidance included

Quarter ended June 30, 2026

Total revenue $28.1 million up 33% year over year from $21.2 million

Net loss $19.3 million worse than $13.6 million in the prior-year quarter

Gross margin 92% improved from 88% in the prior-year quarter

Adjusted EBITDA ($9.8 million) slightly improved from ($10.0 million) in the prior-year quarter

Guidance

Revenue guidance for full-year 2026 increased to $114–$117 million, representing approximately 28–31% growth over prior-year revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/10/2026 - 04:27 PM Accepted by SEC EDGAR 08/10/2026 - 04:27 PM Learn about SEC filing dates

FAQ

How did Ceribell (CBLL) perform financially in Q2 2026?

Ceribell reported Q2 2026 revenue of $28.1 million, up 33% from $21.2 million in Q2 2025. Net loss was $19.3 million, or $0.51 per share, and Adjusted EBITDA loss was $9.8 million, reflecting continued investment and negative profitability.

What were Ceribell (CBLL)’s key revenue drivers in Q2 2026?

Growth was driven by both product and subscription sales. Product revenue was $21.2 million and subscription revenue $6.9 million, each growing around 30% year over year, supported by new account additions and higher utilization in existing accounts.

What guidance did Ceribell (CBLL) give for full-year 2026 revenue?

Ceribell raised its 2026 revenue outlook to $114–$117 million, representing approximately 28–31% growth over prior-year revenue. Management cited continued momentum in both new account additions and utilization within the established account base.

What is Ceribell (CBLL)’s profitability and margin profile in Q2 2026?

Ceribell posted a Q2 2026 gross margin of 92%, up from 88% a year earlier, on gross profit of $25.9 million. However, higher operating expenses led to a net loss of $19.3 million and Adjusted EBITDA loss of $9.8 million for the quarter.

How strong is Ceribell (CBLL)’s balance sheet and liquidity?

As of June 30, 2026, Ceribell held $129.3 million in cash, cash equivalents, and marketable securities. In August 2026, it also secured a new credit facility with access to up to $60 million in committed capital, plus $25 million of uncommitted capital.

What recent regulatory and reimbursement milestones has Ceribell (CBLL) achieved?

Ceribell received multiple FDA 510(k) clearances for detection algorithms and new hardware designs, and obtained a New Technology Add-On Payment from CMS for its delirium monitoring solution, effective October 1, 2026, supporting adoption and hospital economics.

How many active accounts did Ceribell (CBLL) have at the end of Q2 2026?

Ceribell ended the second quarter of 2026 with 712 total active accounts. Management highlighted accelerating adoption across both new and existing accounts as a key driver of its recurring revenue and overall growth trajectory.

false000186110700018611072026-08-102026-08-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2026

CeriBell, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42364		47-1785452
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)
360 N. Pastoria Avenue Sunnyvale, California				94085
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (800) 436-0826

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		CBLL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 10, 2026, CeriBell, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026. A copy of the press release, dated August 10, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01	Financial Statements and Exhibits.
Exhibit No.		Description
99.1		Press Release of CeriBell, Inc., dated August 10, 2026.
104		Cover Page Interactive Data File, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				CERIBELL, INC.
Date: August 10, 2026				By:		/s/ Scott Blumberg
						Scott Blumberg
						Chief Financial Officer

Ceribell Reports Second Quarter 2026 Financial Results

Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 & Recent Highlights

•Reported total revenue of $28.1 million in the second quarter of 2026, a 33% increase compared to the same period in 2025

•Ended the quarter with 712 total active accounts

•Achieved gross margin of 92%, which includes impact of refunds from previously paid tariffs

•Received U.S. Food and Drug Administration 510(k) clearances for Epileptiform Abnormality Detection algorithm and Artifact Reduction algorithm

•Received multiple U.S. Food and Drug Administration 510(k) clearances for new recorder and headband designs that will form the foundation of Ceribell’s next-generation hardware platform

•Announced publication of study in Critical Care Medicine reinforcing the link between Clarity-measured seizure burden and neurological outcomes

•Secured new credit facility to refinance existing debt, providing access to up to $60 million of committed capital

•Received New Technology Add-On Payment (NTAP) for delirium monitoring solution from Centers for Medicare & Medicaid Services, effective October 1, 2026

•Strengthened Board of Directors with the appointment of Tom West and Sharon O’Keefe

"Our second quarter results reflect adoption accelerating across both new and existing accounts," said co-founder and CEO Jane Chao, Ph.D. "Combined with the early progress of our delirium pilot and multiple new FDA 510(k) clearances, we are highly confident in the strength of our business and our mission to establish EEG as a new vital sign."

Second Quarter 2026 Financial Results

Total revenue in the second quarter of 2026 was $28.1 million, a 33% increase from $21.2 million in the second quarter of 2025. The increase was primarily driven by continued growth in new account additions and increased utilization within the Company's existing account base, which grew despite the seasonal moderation in ICU census typically experienced during the summer months. Product revenue for the second quarter of 2026 was $21.2 million, representing an increase of 33% from $15.9 million in the second quarter of 2025. Subscription revenue for the second quarter of 2026 was $6.9 million, representing an increase of 30% from $5.3 million in the second quarter of 2025, reflecting continued growth in the Company’s installed base of Clarity subscriptions.

Gross profit in the second quarter of 2026 was $25.9 million, compared to $18.7 million for the second quarter of 2025. Gross margin for the second quarter of 2026 was 92%, compared to 88% for the same period in 2025. Gross margins improved due to manufacturing cost reduction initiatives and the impact of the Company's introduction of a fully operational manufacturing line in Vietnam. The Company also recognized a one-time benefit of tariff refunds previously paid under the International Emergency Economic Powers Act (“IEEPA”).

Operating expenses in the second quarter of 2026 were $45.9 million, compared to $33.6 million for the second quarter of 2025, representing an increase of 37%. The increase in operating expenses was primarily attributable to continued

investments in the Company’s commercial organization, increased headcount and related payroll and stock-based compensation expenses to support the growth of the business and expansion of its product pipeline, and legal costs associated with intellectual property enforcement activities, including the patent infringement suit initiated against Natus Medical Incorporated in July 2025.

Net loss in the second quarter of 2026 was $19.3 million, or $0.51 net loss per share, compared to a net loss of $13.6 million, or $0.38 net loss per share, for the same period in 2025.

Adjusted EBITDA loss (a non-GAAP measure) for the second quarter of 2026 was $9.8 million, compared to $10.0 million in the second quarter of 2025. Reconciliations of EBITDA and Adjusted EBITDA for the three months ended June 30, 2026 and 2025 are in the financial schedules that are included with this press release.

Cash, cash equivalents, and marketable securities totaled $129.3 million as of June 30, 2026. In August 2026, the Company further strengthened its balance sheet by entering into a new credit facility providing access to up to $60 million in committed capital, comprising a $30 million term loan and a $30 million revolving credit facility, with an additional $25 million of uncommitted capital available at the lender's discretion.

2026 Financial Outlook

Ceribell is raising its revenue guidance for the full year 2026 to a range of $114 million to $117 million, representing growth of approximately 28% to 31% over the Company’s prior year revenue. This update reflects the Company’s continued momentum in its core business, driven by both new account additions and increased utilization within its established account base.

Webcast and Conference Call Details

Ceribell will host a conference call today, August 10, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter 2026 financial results. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 1880547. A live and archived webcast of the event will be available on the “Investor Relations” section of the Ceribell website at https://investors.ceribell.com/.

Forward-Looking Statements

Except where otherwise noted, the information contained in this earnings release and the related attachments is as of August 10, 2026. We assume no obligation to update any forward-looking statements contained in this earnings release and the related attachments as a result of new information or future events or developments. This earnings release and the related attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties, and assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope,” and other words and terms of similar meaning. Our financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market acceptance and adoption of our products; competitive pressures; our manufacturing operations, including our reliance on third-party manufacturers and suppliers in China and Vietnam and our ability to adapt to evolving demand; product defects or complaints and related liability; the complexity, timing, expense, and outcomes of clinical studies, legal matters and regulatory compliance; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; geopolitical conflicts and related supply chain disruptions; and other risks and uncertainties, including those described under the heading “Risk

Factors” in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as in other reports filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.ceribell.com/ and on the SEC’s website at https://sec.gov/.

Non-GAAP Financial Measures

EBITDA and Adjusted EBITDA are non-GAAP financial measures. Ceribell defines EBITDA as GAAP net loss adjusted to exclude (i) provision for income taxes (ii) depreciation and amortization expense, and (iii) interest income and interest expense, net. EBITDA is then adjusted to exclude (iv) stock-based compensation expense and (v) legal fees and related professional services costs incurred in connection with the patent infringement action we filed against Natus Medical Incorporated and certain of its subsidiaries in July 2025, as further described in Part II, Item 1 — Legal Proceedings of Ceribell's Quarterly Report on Form 10-Q, to arrive at Adjusted EBITDA. Management uses EBITDA and Adjusted EBITDA to evaluate ongoing operations and for internal planning and forecasting purposes. Ceribell believes EBITDA and Adjusted EBITDA provide investors with meaningful supplemental information regarding its performance by excluding certain items that may not be indicative of its business, results of operations, or outlook. EBITDA and Adjusted EBITDA should not be considered in isolation, as a substitute for, or superior to GAAP net loss, and may not be comparable to similarly titled measures used by other companies. Reconciliations between U.S. GAAP and non-GAAP results are presented in the accompanying tables of this release.

About CeriBell, Inc.

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contacts

Brian Johnston

Gilmartin Group

Investors@ceribell.com

Media Contact

Brian Price

Press@ceribell.com

CeriBell, Inc.

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

(unaudited)

		Three months ended June 30,								Six months ended June 30,
		2026				2025				2026				2025
Revenue
Product revenue		$	21,241			$	15,923			$	41,431			$	31,531
Subscription revenue			6,856				5,276				13,160				10,159
Total revenue			28,097				21,199				54,591				41,690
Cost of revenue
Product cost of goods sold			1,830				2,351				4,898				4,711
Subscription cost of revenue			329				166				633				290
Total cost of revenue			2,159				2,517				5,531				5,001
Gross profit			25,938				18,682				49,060				36,689
Operating expenses
Research and development			6,747				4,852				12,908				9,098
Sales and marketing			24,415				17,422				46,805				35,455
General and administrative			14,757				11,360				30,073				21,295
Total operating expenses			45,919				33,634				89,786				65,848
Loss from operations			(19,981	)			(14,952	)			(40,726	)			(29,159	)
Interest expense			(438	)			(477	)			(872	)			(948	)
Other income, net			1,151				1,786				2,593				3,687
Loss before provision for income taxes			(19,268	)			(13,643	)			(39,005	)			(26,420	)
Provision for income tax expense			—				—				—				—
Net loss		$	(19,268	)		$	(13,643	)		$	(39,005	)		$	(26,420	)
Net loss per share attributable to common stockholders:
Basic and diluted			(0.51	)			(0.38	)			(1.03	)			(0.73	)
Weighted-average shares used in computing net loss per share attributable to common stockholders:
Basic and diluted			38,031,928				36,293,559				37,848,625				36,088,433
Other comprehensive loss
Net unrealized gain (loss) on marketable securities		$	(110	)		$	11			$	(251	)		$	5
Comprehensive loss		$	(19,378	)		$	(13,632	)		$	(39,256	)		$	(26,415	)

CeriBell, Inc.

Condensed Balance Sheets

(in thousands, except share and per share data)

(unaudited)

		June 30,				December 31,
		2026				2025
Assets
Current assets
Cash and cash equivalents		$	32,663			$	40,476
Marketable securities			96,598				118,785
Accounts receivable, net			15,995				15,053
Inventory			6,737				7,288
Contract costs, current			2,196				2,210
Prepaid expenses and other current assets			3,658				2,906
Total current assets			157,847				186,718
Property and equipment, net			1,760				2,030
Operating lease right-of-use assets			1,781				2,296
Contract costs, long-term			1,540				1,847
Other non-current assets			3,420				2,912
Total assets		$	166,348			$	195,803
Liabilities and stockholders’ equity
Current liabilities
Accounts payable		$	3,185			$	2,838
Accrued liabilities			12,481				14,328
Contract liabilities, current			11			101
Operating lease liability, current			1,180				1,105
Other current liabilities			343			818
Total current liabilities			17,200				19,190
Long-term liabilities
Notes payable, long-term			19,981				19,811
Other liabilities, long-term			106			106
Operating lease liability, long-term			748				1,360
Total long-term liabilities			20,835				21,277
Total liabilities		$	38,035			$	40,467
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.001 par value;
Authorized shares: 10,000,000 as of June 30, 2026 and December 31, 2025, respectively
Issued and outstanding shares: none as of June 30, 2026 and December 31, 2025, respectively			—				—
Common stock, $0.001 par value;
Authorized shares: 500,000,000 as of June 30, 2026 and December 31, 2025, respectively
Issued and outstanding shares: 38,223,221 and 37,485,124 as of June 30, 2026 and December 31, 2025, respectively			39				38
Additional paid-in capital			387,727				375,495
Accumulated other comprehensive income (loss)			(92	)			159
Accumulated deficit			(259,361	)			(220,356	)
Total stockholders’ equity			128,313				155,336
Total liabilities and stockholders’ equity		$	166,348			$	195,803

CeriBell, Inc.

Reconciliation of U.S. GAAP to Non-GAAP Financial Measures

(in thousands)

(unaudited)

		Three months ended June 30,								Six months ended June 30,
		2026				2025				2026				2025
Net Loss (GAAP)		$	(19,268	)		$	(13,643	)		$	(39,005	)		$	(26,420	)
Non-GAAP Adjustments:
Interest (income) and expense, net			(712	)			(1,308	)			(1,701	)			(2,739	)
Depreciation and amortization			245				324				484				659
EBITDA (Non-GAAP)			(19,735	)			(14,627	)			(40,222	)			(28,500	)
Stock-based compensation			5,998				3,167				9,721				5,515
IP litigation matter			3,913				1,429				9,507				2,053
Adjusted EBITDA (Non-GAAP)		$	(9,824	)		$	(10,031	)		$	(20,994	)		$	(20,932	)

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 396.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.7 KB